Resources from the same session
42O - A phase Ia/b, dose-escalation and expansion study evaluating the MDM2–p53 antagonist BI 907828 in patients with solid tumours: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS)
Presenter: Patrick Schoeffski
Session: Proffered paper session – Sarcoma
Resources:
Abstract
Slides
Webcast
43O - MDM2 inhibitor milademetan: Safety profile and management of adverse events (AEs)
Presenter: Chiara Fabbroni
Session: Proffered paper session – Sarcoma
Resources:
Abstract
Slides
Webcast
44O - Comparison of clinical outcomes of patients with infantile fibrosarcoma (IFS) treated with larotrectinib in the SCOUT study versus historical cohort: The EPI-VITRAKVI study
Presenter: Daniel Orbach
Session: Proffered paper session – Sarcoma
Resources:
Abstract
Slides
Webcast
45O - Clonal evolution of dedifferentiated liposarcoma
Presenter: TETSUYA SEKITA
Session: Proffered paper session – Sarcoma
Resources:
Abstract
46O - Integrated molecular analysis of human dedifferentiated liposarcoma identifies a population of tumoral progenitors vulnerable to TGF beta inhibition
Presenter: Sarah Watson
Session: Proffered paper session – Sarcoma
Resources:
Abstract
Invited discussant
Presenter: Eva Wardelmann
Session: Proffered paper session – Sarcoma
Resources:
Slides
Webcast
Q&A
Presenter: Judith Bovée
Session: Proffered paper session – Sarcoma
Resources:
Webcast